- Home
- EAD vs BDTX Comparison
EAD vs BDTX Comparison
Compare EAD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | BDTX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.0M | 171.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EAD | BDTX |
|---|---|---|
| Price | $6.18 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 212.7K | ★ 503.7K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $1.60 |
| 52 Week High | $7.10 | $4.94 |
Technical Indicators
Market Signals| Indicator | EAD | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 43.63 |
| Support Level | N/A | $1.61 |
| Resistance Level | $6.44 | $2.28 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 24.12 | 12.70 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. The Fund seeks a high level of current income. Capital appreciation is a secondary objective. The fund has single operating segment.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.